By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Allergan Inc. 

2525 Dupont Drive

Irvine  California  92612  U.S.A.
Phone: 714-246-4500 Fax: n/a


SEARCH JOBS

Allergan is a multi-specialty health care company established more than 60 years ago with a commitment to uncover the best of science and develop and deliver innovative and meaningful treatments to help people reach their life’s potential. Today, we have approximately 11,100 highly dedicated and talented employees, global marketing and sales capabilities with a presence in more than 100 countries, a rich and ever-evolving portfolio of pharmaceuticals, biologics, medical devices and over-the-counter consumer products, and state-of-the-art resources in R&D, manufacturing and safety surveillance that help millions of patients see more clearly, move more freely and express themselves more fully. For the year ending 2012, our total product net sales totaled $5.5 billion, a 10 percent increase over 2011. From our beginnings as an eye care company to our focus today on several medical specialties, including eye care, neurosciences, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention and urologics, Allergan is proud to celebrate more than six decades of medical advances and proud to support the patients and physicians who rely on our products and the employees and communities in which we live and work. For more information regarding Allergan, go to: www.allergan.com.


Key Statistics


Email: Corpinfo@allergan.com
Ownership: Public

Web Site: Allergan
Employees: 11,100
Symbol: AGN
 



Industry
Pharmaceutical


Collaborations

Elan Pharmaceuticals 

CeNes Pharmaceuticals (U.S.) 

PanVera LLC 

Pharmagene Laboratories Limited  Phase ZERO(TM) products and services.

Acadia  Discovery of alpha adrenergic drug candidates that may represent a significant breakthrough in the treatment of neuropathic pain.

Acadia  Develop and commercialize selective muscarinic drugs for the treatment of glaucoma.

Acadia  The third collaboration is designed to leverage ACADIA's R&D platform to discover and develop new therapeutics predominantly in the area of pain.





Company News
FTC May Require Products Worth $600 Million to be Divested for Teva (TEVA)-Allergan (AGN) Deal to Go Through 8/27/2015 7:03:35 AM
Allergan (AGN) And Gedeon Richter Ltd. (RIG2.F) To Present Data From Cariprazine Trials At European College Of Neuropsychopharmacology (ECNP) Annual Meeting In Amsterdam 8/25/2015 6:42:26 AM
Allergan (AGN) Issues Voluntary Nationwide Recall In The U.S. Of Specific Lots Of REFRESH Lacri-Lube, REFRESH P.M. , FML (fluorometholone ophthalmic ointment) 0.1%, And Blephamide (sulfacetamide Sodium And Prednisolone Acetate Ophthalmic Ointment, USP) 10%/0.2% For Particulate Matter 8/24/2015 7:41:05 AM
Allergan (AGN) Release: FDA Accepts BOTOX (onabotulinumtoxinA) Resubmission For The Treatment Of Lower Limb Spasticity In Adults 8/20/2015 6:44:36 AM
Allergan (AGN) Confirms Generic Noxafil Patent Challenge 8/12/2015 6:17:13 AM
Allergan (AGN) Successfully Completes Oculeve Acquisition 8/11/2015 6:53:53 AM
Allergan (AGN) Reports Exceptional Second Quarter 2015 Performance With 116% Increase In Net Revenue To $5.76 Billion And 29% Growth In Non-GAAP EPS To $4.41 8/6/2015 10:59:33 AM
Amidst Allergan (AGN) Acquisition and Immuneering Investment, Teva (TEVA) Slashes More Jobs in Virginia 8/6/2015 6:52:16 AM
FDA Approves 28 Additional Styles Of Allergan (AGN)'s Natrelle 410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implants 8/6/2015 6:32:16 AM
Ironwood (IRWD) And Allergan (AGN) Enter Agreement To Co-Promote VIBERZI For Irritable Bowel Syndrome With Diarrhea (IBS-D) In The U.S. 8/5/2015 11:21:49 AM
12345678910...
//-->